blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1894571

EP1894571 - Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  25.07.2008
Database last updated on 30.09.2024
Most recent event   Tooltip25.07.2008Withdrawal of applicationpublished on 27.08.2008  [2008/35]
Applicant(s)For all designated states
ProtAffin Biotechnologie AG
Impulszentrum Graz-West
Reininghausstrasse 13a
8020 Graz / AT
[N/P]
Former [2008/10]For all designated states
Protaffin Biotechnologie AG
Impulszentrum Graz-West Reininghausstrasse 13a
8020 Graz / AT
Inventor(s)01 / Kungl, Andreas.J.
Strasserhofweg 77a
8045 Graz / AT
02 / Bedke, Jens
Hauptstrasse 50
69221 Dossenheim / DE
03 / Gröne, Hermann-Josef
Im Moselsgrund 17
69118 Heidelberg / DE
 [2008/10]
Representative(s)SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
[N/P]
Former [2008/10]Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
Application number, filing date06450117.429.08.2006
[2008/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1894571
Date:05.03.2008
Language:EN
[2008/10]
Search report(s)(Supplementary) European search report - dispatched on:EP26.03.2007
ClassificationIPC:A61K38/20, C12N15/00, A61P37/06
[2008/10]
CPC:
A61K38/2053 (EP,US); A61K38/13 (EP,US); A61P37/06 (EP);
A61P39/00 (EP); C07K14/5421 (EP,US)
C-Set:
A61K38/13, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/10]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:Verwendung von modifizierten IL-8 Proteinen zur Behandlung von Reperfusionsschäden und Transplantatabstossung[2008/10]
English:Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection[2008/10]
French:Utilisations de protéines IL-8 modifiées pour traiter les dommages dûs à la reperfusion et le rejet de greffe[2008/10]
Examination procedure15.07.2008Application withdrawn by applicant  [2008/35]
Fees paidRenewal fee
10.03.2008Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[AD]US5665346  (CLARK-LEWIS IAN [CA], et al) [AD] 1-11 * see abstract, col.6 lines 7-20, col.1 lines 55-60 *;
 [Y]WO2004058189  (UNIV TEXAS [US]) [Y] 1-11* see claims 1,4,40, page 24 table 1 *;
 [YD]WO2005054285  (KUNGL ANDREAS J [AT]) [YD] 1-11 * see claims 1-14, 21-22 and page 3 table 1 *;
 [DY]  - CUGINI D. ET AL., "Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion", KIDNEY INTERNATIONAL, (2005), vol. 67, pages 1753 - 1761, XP002421838 [DY] 1-11 * see abstract and pages 1753-1754 *

DOI:   http://dx.doi.org/10.1111/j.1523-1755.2005.00272.x
 [A]  - KUSCHERT G S V ET AL, "Identification of a glycosaminoglycan binding surface on human interleukin-8", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, (19980811), vol. 37, no. 32, ISSN 0006-2960, pages 11193 - 11201, XP002273720 [A] 1-11 * see abstract *

DOI:   http://dx.doi.org/10.1021/bi972867o
 [A]  - WILLIAMS GLYN ET AL, "Mutagenesis studies of interleukin-8: Identification of a second epitope involved in receptor binding", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (1996), vol. 271, no. 16, ISSN 0021-9258, pages 9579 - 9586, XP002410539 [A] 1-11 * see abstract *

DOI:   http://dx.doi.org/10.1074/jbc.271.16.9579
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.